BRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma

被引:9
作者
Collet, Jean-Francois [1 ,2 ]
Lacave, Roger [3 ]
Hugonin, Sylvain [3 ]
Poulot, Virginie [3 ]
Tassart, Marc [4 ]
Fajac, Anne [1 ]
机构
[1] Hop Tenon HUEP, AP HP, Anat & Cytol Pathol, 4 Rue Chine, F-75020 Paris, France
[2] Inst Pathol, Paris, France
[3] Hop Tenon HUEP, AP HP, Unit Genom Tumeurs Solides, Paris, France
[4] Hop Tenon HUEP, AP HP, Radiol, Paris, France
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2016年 / 38卷 / 07期
关键词
BRAF; papillary thyroid cancer; fine-needle aspiration (FNA); cytology; preoperative diagnosis; MUTATION; RECURRENCE;
D O I
10.1002/hed.24393
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Whether preoperative knowledge of the BRAF mutation status would help to determine the extent of surgery for thyroid nodules is still under investigation. Methods. We developed a method to state the V600E mutation before surgery on fine-needle aspiration (FNA) stained smears checked to contain tumor cells. We evaluated the interest of the preoperative assessment of the mutation for surgical strategy of nodules, diagnosed as malignant, suspicious for malignancy or follicular neoplasms. Results. The mutation was found in 81% (79 of 97) malignant, 59% (20 of 34) suspicious nodules, and in none of follicular neoplasms (n = 29). Overall, the mutation was detected in 82% of papillary carcinomas. The sensitivity, specificity, and positive and negative predictive values for the diagnosis of malignancy were 75%, 100%, 100%, and 46%, respectively. Conclusion. The preoperative knowledge of the V600E mutation status is fundamental to plan total thyroidectomy with certainty and should be part of the decision tree for the management of thyroid nodules. (C) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:1017 / 1021
页数:5
相关论文
共 24 条
  • [21] BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
    Xing, MZ
    Westra, WH
    Tufano, RP
    Cohen, Y
    Rosenbaum, E
    Rhoden, KJ
    Carson, KA
    Vasko, V
    Larin, A
    Tallini, G
    Tolaney, S
    Holt, EH
    Hui, P
    Umbricht, CB
    Basaria, S
    Ewertz, M
    Tufaro, AP
    Califano, JA
    Ringel, MD
    Zeiger, MA
    Sidransky, D
    Ladenson, PW
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (12) : 6373 - 6379
  • [22] Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation
    Yip, Linwah
    Nikiforova, Marina N.
    Carty, Sally E.
    Yirn, John H.
    Stang, Michael T.
    Tublin, Mitchell J.
    LeBeau, Shane O.
    Hodak, Steven P.
    Ogilvie, Jennifer B.
    Nikiforov, Yuri E.
    [J]. SURGERY, 2009, 146 (06) : 1215 - 1223
  • [23] Effect of reoperation on outcomes in papillary thyroid cancer
    Young, Stephanie
    Harari, Avital
    Smooke-Praw, Stephanie
    Ituarte, Philip H. G.
    Yeh, Michael W.
    [J]. SURGERY, 2013, 154 (06) : 1354 - 1361
  • [24] Value of Immunohistochemistry in the Detection of BRAFV600E Mutations in Fine-Needle Aspiration Biopsies of Papillary Thyroid Carcinoma
    Zimmermann, Anne-Katrin
    Camenisch, Ulrike
    Rechsteiner, Markus P.
    Bode-Lesniewska, Beata
    Roessle, Matthias
    [J]. CANCER CYTOPATHOLOGY, 2014, 122 (01) : 48 - 58